Skip to Content
Merck
  • Development of isoform selective PI3-kinase inhibitors as pharmacological tools for elucidating the PI3K pathway.

Development of isoform selective PI3-kinase inhibitors as pharmacological tools for elucidating the PI3K pathway.

Bioorganic & medicinal chemistry letters (2012-08-07)
Ian Bruce, Mohammed Akhlaq, Graham C Bloomfield, Emma Budd, Brian Cox, Bernard Cuenoud, Peter Finan, Peter Gedeck, Julia Hatto, Judy F Hayler, Denise Head, Thomas Keller, Louise Kirman, Catherine Leblanc, Darren Le Grand, Clive McCarthy, Desmond O'Connor, Charles Owen, Mrinalini S Oza, Gaynor Pilgrim, Nicola E Press, Lilya Sviridenko, Lewis Whitehead
ABSTRACT

Using a parallel synthesis approach to target a non-conserved region of the PI3K catalytic domain a pan-PI3K inhibitor 1 was elaborated to provide alpha, delta and gamma isoform selective Class I PI3K inhibitors 21, 24, 26 and 27. The compounds had good cellular activity and were selective against protein kinases and other members of the PI3K superfamily including mTOR and DNA-PK.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
2-Aminothiazole, 97%